ACYCLOVIR THERAPY FOR MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN IMMUNOCOMPROMISED PATIENTS

Charles D. Mitchell, Sharron R. Gentry, James R. Boen, Bonnie Bean, Karl E. Groth, Henry H Balfour

Research output: Contribution to journalArticle

130 Scopus citations

Abstract

11 of 24 immunocompromised patients with mucocutaneous herpes simplex virus (HSV) infections were given intravenous acyclovir in a randomised double-blind placebo-controlled study. Patients receiving acyclovir experienced no major adverse effects. The median times to cessation of new lesion formation, lesion crusting, lesion healing, cessation of pain, and termination of viral shedding were shorter in the acyclovir-treated group than in the placebo group. The time-to-event probability curves for the acyclovir and placebo groups were significantly different for cessation of pain (p = 0.032) and termination of viral shedding (p = 0.004). The median times to termination of viral shedding were also statistically different (p = 0.045). Acyclovir seems to be a non-toxic and effective treatment for mucocutaneous HSV infections in immunocompromised patients.

Original languageEnglish (US)
Pages (from-to)1389-1392
Number of pages4
JournalThe Lancet
Volume317
Issue number8235
DOIs
StatePublished - Jun 27 1981

Fingerprint Dive into the research topics of 'ACYCLOVIR THERAPY FOR MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN IMMUNOCOMPROMISED PATIENTS'. Together they form a unique fingerprint.

  • Cite this